Oncology Drug Targets Exploiting Targeted Protein Degradation (TPD)

A multinational pharmaceutical company is seeking first-in-class novel/established drug targets for Targeted Protein Degradation (TPD), especially proteolysis-targeting chimeras (PROTACs) in oncology. Priority cancers of interest are biliary tract cancer, pancreatic cancer, non-small cell lung cancer (PD-L1 negative), prostate cancer (castration-resistant), urothelial cancer, acute myeloid leukaemia. Other cancers such as breast cancer (triple-negative), ovarian cancer (platinum-resistant), soft tissue sarcoma and diffuse large B-cell lymphoma are also of...